Skip to Main Content

Author Details

Jan Paul Medema
Oncode Institute
1993
242
72
PMIDPaper TitleJournal TitlePublished Year
36069222Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.Int J Cancer2023
37681286Consensus molecular subtype transition during progression of colorectal cancer.J Pathol2023
37383222Kinase-targeted therapy in subsets of colorectal cancer.Oncoscience2023
37100955Apoptotic cell death in disease-Current understanding of the NCCD 2023.Cell Death Differ2023
36869386Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.J Exp Clin Cancer Res2023
33436496PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.Gut2022
35798962Accurate staging of non-metastatic colon cancer with CT: the importance of training and practice for experienced radiologists and analysis of incorrectly staged cases.Abdom Radiol (NY)2022
35413826Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.BMC Cancer2022
35905558Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer.Cancer Treat Rev2022
36334593Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer.Cell Rep Med2022
35927254Molecular characterization of colorectal cancer related peritoneal metastatic disease.Nat Commun2022
36293565Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients.Int J Mol Sci2022
35172148BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer.Cell Rep2022
33397922A RAC-GEF network critical for early intestinal tumourigenesis.Nat Commun2021
33673003AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition.Cancers (Basel)2021
33917026BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.Int J Mol Sci2021
33745794Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome.Eur J Surg Oncol2021
34408135Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery.Nat Commun2021
34572947The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis.Cancers (Basel)2021
34712995FACS-based protocol to assess cytotoxicity and clonogenic potential of colorectal cancer stem cells using a Wnt/β-catenin signaling pathway reporter.STAR Protoc2021
34079128Apc-mutant cells act as supercompetitors in intestinal tumour initiation.Nature2021
34045449Chromosomal copy number heterogeneity predicts survival rates across cancers.Nat Commun2021
34068407Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression.Cancers (Basel)2021
34117376BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer.Cell Death Differ2021
34162659Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers.Cancer Epidemiol Biomarkers Prev2021
32458162Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN).Eur J Health Econ2020
31733011Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma.Mol Oncol2020
31931052Nanostructured toxins for the selective destruction of drug-resistant human CXCR4<sup>+</sup> colorectal cancer stem cells.J Control Release2020
31941932Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems.Sci Rep2020
32965059RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer.EMBO J2020
32989144Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity.Proc Natl Acad Sci U S A2020
32647253Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges.Oncogenesis2020
32335811BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy.Apoptosis2020
32173982High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1.EMBO Rep2020
30414058Isolation, Propagation, and Clonogenicity of Intestinal Stem Cells.Methods Mol Biol2019
30151914Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.Int J Cancer2019
31526760Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.Cancer Cell2019
31018252Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.Int J Cancer2019
30850544Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts.Proc Natl Acad Sci U S A2019
30670657Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.Proc Natl Acad Sci U S A2019
29300042Escape from senescence boosts tumour growth.Nature2018
32086500Escape from senescence boosts tumour growth.Nature2018
29885883microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.Gastroenterology2018
29988089Translational repression of pre-formed cytokine-encoding mRNA prevents chronic activation of memory T cells.Nat Immunol2018
30177776Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.Nat Cell Biol2018
29869097Patched-2 functions to limit Patched-1 deficient skin cancer growth.Cell Oncol (Dordr)2018
30442938ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.Oncogenesis2018
29362479Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.Cell Death Differ2018
29354056Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids.Front Pharmacol2018
29305587Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.Cell Death Differ2018
  • 1 - 50 of 242

Recommended Authors

Radek Fedr
Institute of Biophysics of the Czech Academy of Sciences
Career Start Year 2013
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 1
Jianying Zhang
City of Hope National Medical Center
Career Start Year 2009
Number of shared co-authors 0
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 1
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Susan L Woods
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 2
Darren L Roberts
The University of Manchester
Career Start Year 2001
Number of shared co-authors 0
Beate Rinner
Medical University of Graz
Career Start Year 2000
Number of shared co-authors 0
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 4
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Erxi Wu
Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Career Start Year 1997
Number of shared co-authors 2
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 0
Hae-Ock Lee
College of Medicine, The Catholic University of Korea
Career Start Year 1996
Number of shared co-authors 0
John M Mariadason
Olivia Newton-John Cancer Research Institute
Career Start Year 1996
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 2
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 2
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 0
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 5
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 0
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Career Start Year 1992
Number of shared co-authors 2
Laurie Ailles
University of Toronto
Career Start Year 1991
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 14
Roger Chammas
Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina de Sao Paulo
Career Start Year 1989
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 8
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 6
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 8
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 2
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 7
David J McConkey
Johns Hopkins School of Medicine
Career Start Year 1986
Number of shared co-authors 48
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 2

Collaborators

Louis Vermeulen
Oncode Institute
Co-authored papers 50
Hanneke W M van Laarhoven
Cancer Center Amsterdam
Co-authored papers 18
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Co-authored papers 11
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 9
Jan Koster
Amsterdam University Medical Centers location AMC
Co-authored papers 9
Tijana Borovski
Cancer Center, University Medical Center Utrecht
Co-authored papers 9
Kausilia K Krishnadath
Antwerp University Hospital
Co-authored papers 8
Lukas J A Stalpers
Co-authored papers 6
René E M Toes
Co-authored papers 6
Remond J A Fijneman
The Netherlands Cancer Institute
Co-authored papers 5
Carlos L??pez-Ot??n
Instituto Universitario de Oncologia, Universidad de Oviedo
Co-authored papers 4
Ted M Dawson
Johns Hopkins University School of Medicine
Co-authored papers 4
Brent R Stockwell
Columbia University
Co-authored papers 4
Rosario Rizzuto
Co-authored papers 4
Tom van der Poll
Center for Experimental and Molecular Medicine, University of Amsterdam
Co-authored papers 4
Valina L Dawson
Institute for Cell Engineering, Johns Hopkins University School of Medicine
Co-authored papers 4
Gerrit A Meijer
The Netherlands Cancer Institute
Co-authored papers 4
Simone Fulda
Co-authored papers 4
Brian D Dynlacht
New York University Cancer Institute, New York University School of Medicine
Co-authored papers 4
Cornelis J H van de Velde
Leiden University Medical Center: Leids Universitair Medisch Centrum.
Co-authored papers 4
Joost J C Verhoeff
University Medical Center Utrecht
Co-authored papers 4
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 4
Stuart A Lipton
The Scripps Research Institute, University of California
Co-authored papers 4
Nicola Di Daniele
University of Rome Tor Vergata
Co-authored papers 3
Evripidis Gavathiotis
Albert Einstein College of Medicine
Co-authored papers 3
Jerry E Chipuk
Co-authored papers 3
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 3
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 3
Mauro Delorenzi
Co-authored papers 2
Martijn G H van Oijen
University of Amsterdam, Cancer Center Amsterdam
Co-authored papers 2
Release 1.2